Qiagen (QGEN) investor relations material

Opening remarks and agenda

• Meeting opened by the Chairman, with Supervisory and Managing Board members, auditors, and legal counsel present.

• Procedural details covered, including webcast, language, and voting rights; over 50% of share capital represented.

• The meeting was held on June 24, 2026, in Venlo, the Netherlands, with a comprehensive agenda covering financial, strategic, and governance topics.

Financial performance review

• 2025 sales reached $2.09 billion, up 6% reported and 5% at constant exchange rates.

• Adjusted operating income margin rose to 29.5%, with adjusted EPS up 9% to $2.40 (CER).

• Operating cash flow was $654 million, supporting investments and shareholder returns.

• Growth pillars delivered $1.49 billion in sales, with QIAstat-Dx and QuantiFERON as key drivers.

• R&D expenses held at 9% of sales; sales and marketing expenses declined as digital channels increased.

Board and executive committee updates

• Significant renewal of the Supervisory Board, with seven of eight members joining since 2021.

• New Supervisory Board members with significant industry experience were welcomed, including Mark P. Stevenson and Robert McMahon.

• Dr. Metin Colpan was honored as Honorary Chairman of the Supervisory Board.

• Managing Board members reappointed until 2027, with CEO succession planned.

• Reappointments of Managing Directors Thierry Bernard and Roland Sackers were proposed.